玻璃体腔注射阿柏西普治疗息肉状脉络膜血管病变的两年疗效与安全性
这项前瞻性多中心随机双盲假手术对照3b/4期研究,纳入息肉状脉络膜血管病变(PCV)患者,比较玻璃体腔阿柏西普单药(IAI)与IAI联合补救性光动力疗法(rPDT)的长期疗效与安全性。
要点
- IAI单药在96周BCVA获益上非劣于联合rPDT,且52周功能与解剖改善得以维持。
- 仅17.0%患者触发补救标准,rPDT未提供额外视力获益。
- 第二年两组平均注射次数均为4.6次,无新安全性信号。
核心结论
- IAI单药治疗至96周非劣于IAI联合补救性PDT,52周获得的功能和解剖改善得以维持。
- 需要补救PDT的患者很少,且补救PDT未提供额外视力获益。
研究设计与样本
- 前瞻性多中心、双盲、假手术对照随机临床试验,覆盖62个中心,为3b/4期研究。
- PCV患者BCVA为73-24个ETDRS字母(Snellen等效20/40-20/320),初始每4周接受IAI 2mg至第12周,随后1:1随机接受IAI或IAI联合rPDT(满足补救标准时)。
主要发现
- 96周内54例患者(17.0%)满足补救标准。
- 完全息肉消退比例分别为33.1% vs 29.1%,无活动性息肉比例分别为82.1% vs 85.6%,两组相似。
- 第二年两组平均注射次数均为4.6次,未观察到新的安全性信号。
关键数值与推荐
- 主要终点为第52周,IAI非劣于IAI+rPDT。
- 第52周后研究者可酌情将治疗间隔延长至超过8周。
- 第96周评估IAI vs IAI+rPDT在BCVA较基线变化上的非劣效性。
临床怎么用
- IAI单药可作为PCV的长期治疗选择,无需常规联合PDT。
- 仅少数患者需补救PDT,且补救PDT未带来额外视力获益。
- 治疗间期可根据情况延长至超过8周,第二年平均注射4.6次。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We sought to evaluate longer-term efficacy and safety of intravitreal aflibercept monotherapy (IAI) vs IAI plus rescue photodynamic therapy (rPDT) in patients with polypoidal choroidal vasculopathy (PCV). DESIGN: This was a prospective multicenter, double-masked, sham-controlled randomized clinical study across 62 centers. METHODS: In this phase 3b/4 study, patients with PCV with best-corrected visual acuity of 73-24 Early Treatment Diabetic Retinopathy Study letters (20/40-20/320 Snellen equivalent) received IAI 2 mg every 4 weeks until week 12, when they were randomized 1:1 to receive IAI or IAI plus rPDT if rescue criteria were met. Patients not requiring rescue received IAI every 8 weeks; those requiring rescue received IAI every 4 weeks plus sham/active PDT. At week 52 (the primary endpoint), IAI was noninferior to IAI plus rPDT. After week 52, treatment intervals could be extended beyond 8 weeks at the investigators' discretion. Noninferiority of IAI vs IAI plus rPDT for mean best-corrected visual acuity change from baseline to week 96 was evaluated. RESULTS: Over 96 weeks, 54 patients (17.0%) met rescue criteria. At week 96, IAI was noninferior to IAI plus rPDT in terms of Early Treatment Diabetic Retinopathy Study letters gained (+10.7 vs +9.1, P = .48). Proportions of patients with complete polyp regression (33.1% vs 29.1%) or without active polyps (82.1% vs 85.6%) were similar. In year 2, the mean number of injections was 4.6 in both arms. No new safety signals were observed. CONCLUSION: IAI monotherapy was noninferior to IAI with rescue PDT up to 96 weeks, and functional and anatomical improvements achieved at 52 weeks were maintained. Few patients required rescue PDT, which provided no additional visual benefit.
引用
- Wong TY, Ogura Y, Lee WK, et al. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study. Am J Ophthalmol. 2019. PMID: 30849345. doi:10.1016/j.ajo.2019.02.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。